KYTX
Kyverna Therapeutics, Inc.
6.40$
+3.4%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.7% | +418.6% | -6.9% | -6.6% | -10.2% | -14.4% | -13.1% | -17.4% | +57.0% | -12.5% | -14.5% | |
| – | -23.6% | +519.0% | -7.1% | -6.7% | -10.7% | -14.8% | -13.5% | -18.4% | +61.8% | -14.6% | -14.6% | |
| – | +50.9% | +547.3% | -41.3% | -20.5% | -7.7% | -41.1% | -6.0% | -36.1% | +263.2% | -74.1% | -1.2% | |
| – | -25.5% | +542.6% | -6.4% | -7.1% | -11.1% | -15.2% | -12.8% | -19.2% | +63.2% | -15.3% | -15.7% | |
| – | -87.3% | +11.4% | +2.1% | +23.2% | +4.3% | -3.7% | +15.0% | -16.4% | +74.8% | -0.2% | -11.7% | |
| – | +17.7% | +10.1% | +7.4% | +32.0% | +8.9% | -1.4% | +19.5% | -14.9% | +7.7% | -18.7% | -23.2% | |
| – | +4.4% | +27.3% | +4.1% | +1.6% | +0.2% | -9.0% | -0.3% | +3.0% | +7.7% | -50.0% | -23.1% | |
| – | +44.2% | +71.0% | -34.8% | +104.3% | -53.4% | +83.2% | +17.1% | -69.6% | +75.9% | +118.7% | -74.7% | |
| – | – | – | – | – | – | – | – | – | – | +0.3% | +0.3% | |
| – | – | +634.1% | -7.6% | -9.2% | -11.9% | -16.0% | -17.7% | -17.6% | +52.9% | -15.8% | -15.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -44.9% | +81.6% | +0.1% | +0.1% | +0.0% | +0.0% | +0.4% | +8.6% | +28.2% | +0.8% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.